https://www.ajmc.com/view/new-treatment-paradigm-supersedes-abvd-in-advanced-hodgkin-lymphoma-the-echelon1-study
Including the modified brentuximab antibody in the treatment regimen improved modified progression-free survival by 5%, although the rates of neutropenia and...
hodgkin lymphomanewtreatmentparadigmabvd